Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 07 Oct, 15:21 UTC

A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.